These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 24433874)

  • 1. Treatment of indolent primary cutaneous B-cell lymphomas with subcutaneous interferon-alfa.
    Vandersee S; Terhorst D; Humme D; Beyer M
    J Am Acad Dermatol; 2014 Apr; 70(4):709-715. PubMed ID: 24433874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab plus liposomal pegylated doxorubicin in the treatment of primary cutaneous B-cell lymphomas.
    Fabbri A; Cencini E; Alterini R; Rubegni P; Rigacci L; Delfino C; Puccini B; Fimiani M; Bosi A; Bocchia M; Pimpinelli N;
    Eur J Haematol; 2014 Aug; 93(2):129-36. PubMed ID: 24635751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary cutaneous marginal zone B-cell lymphoma: response to treatment and disease-free survival in a series of 137 patients.
    Servitje O; Muniesa C; Benavente Y; Monsálvez V; Garcia-Muret MP; Gallardo F; Domingo-Domenech E; Lucas A; Climent F; Rodriguez-Peralto JL; Ortiz-Romero PL; Sandoval J; Pujol RM; Estrach MT
    J Am Acad Dermatol; 2013 Sep; 69(3):357-65. PubMed ID: 23796549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary Cutaneous B-Cell Lymphoma: Management and Patterns of Recurrence at the Multimodality Cutaneous Lymphoma Clinic of The Ohio State University.
    Haverkos B; Tyler K; Gru AA; Winardi FK; Frederickson J; Hastings J; Elkins C; Zhang X; Xu-Welliver M; Wong HK; Porcu P
    Oncologist; 2015 Oct; 20(10):1161-6. PubMed ID: 26306900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: a prospective controlled trial.
    Wollina U; Looks A; Meyer J; Knopf B; Koch HJ; Liebold K; Hipler UC
    J Am Acad Dermatol; 2001 Feb; 44(2):253-60. PubMed ID: 11174383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term efficacy, curative potential, and prognostic factors of radiotherapy in primary cutaneous B-cell lymphoma.
    Eich HT; Eich D; Micke O; Süttzer H; Casper C; Krieg T; Müller RP
    Int J Radiat Oncol Biol Phys; 2003 Mar; 55(4):899-906. PubMed ID: 12605967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors in primary cutaneous B-cell lymphoma: the Italian Study Group for Cutaneous Lymphomas.
    Zinzani PL; Quaglino P; Pimpinelli N; Berti E; Baliva G; Rupoli S; Martelli M; Alaibac M; Borroni G; Chimenti S; Alterini R; Alinari L; Fierro MT; Cappello N; Pileri A; Soligo D; Paulli M; Pileri S; Santucci M; Bernengo MG;
    J Clin Oncol; 2006 Mar; 24(9):1376-82. PubMed ID: 16492713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory/relapsed cutaneous T-cell lymphoma.
    Aviles A; Neri N; Fernandez-Diez J; Silva L; Nambo MJ
    Hematology; 2015 Oct; 20(9):538-42. PubMed ID: 25592781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab monotherapy for primary cutaneous B-cell lymphoma: response and follow-up in 16 patients.
    Valencak J; Weihsengruber F; Rappersberger K; Trautinger F; Chott A; Streubel B; Muellauer L; Der-Petrossian M; Jonak C; Binder M; Raderer M
    Ann Oncol; 2009 Feb; 20(2):326-30. PubMed ID: 18836086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
    Gellrich S; Muche JM; Wilks A; Jasch KC; Voit C; Fischer T; Audring H; Sterry W
    Br J Dermatol; 2005 Jul; 153(1):167-73. PubMed ID: 16029344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of molecular diagnostics in primary cutaneous B-cell lymphomas in the context of clinical findings, histology, and immunohistochemistry.
    Felcht M; Booken N; Stroebel P; Goerdt S; Klemke CD
    J Am Acad Dermatol; 2011 Jan; 64(1):135-43, 143.e1-4. PubMed ID: 21167409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial.
    Mohr P; Hauschild A; Trefzer U; Enk A; Tilgen W; Loquai C; Gogas H; Haalck T; Koller J; Dummer R; Gutzmer R; Brockmeyer N; Hölzle E; Sunderkötter C; Mauch C; Stein A; Schneider LA; Podda M; Göppner D; Schadendorf D; Weichenthal M
    J Clin Oncol; 2015 Dec; 33(34):4077-84. PubMed ID: 26503196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases.
    Kerl K; Prins C; Saurat JH; French LE
    Br J Dermatol; 2006 Dec; 155(6):1197-200. PubMed ID: 17107389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cutaneous B-cell lymphoma].
    Cortés B; Prins C
    Rev Med Suisse; 2014 Apr; 10(424):738, 740-3. PubMed ID: 24772806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group.
    Keilholz U; Punt CJ; Gore M; Kruit W; Patel P; Lienard D; Thomas J; Proebstle TM; Schmittel A; Schadendorf D; Velu T; Negrier S; Kleeberg U; Lehman F; Suciu S; Eggermont AM
    J Clin Oncol; 2005 Sep; 23(27):6747-55. PubMed ID: 16170182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete remissions in psoralen and UV-A (PUVA)-refractory mycosis fungoides-type cutaneous T-cell lymphoma with combined interferon alfa and PUVA.
    Mostow EN; Neckel SL; Oberhelman L; Anderson TF; Cooper KD
    Arch Dermatol; 1993 Jun; 129(6):747-52. PubMed ID: 8507078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiation therapy in indolent primary cutaneous B cell lymphoma: a single institute experience.
    De Felice F; Grapulin L; Pieroni A; Salerno F; D'Elia GM; Pulsoni A; Musio D; Tombolini V
    Ann Hematol; 2018 Dec; 97(12):2411-2416. PubMed ID: 30094511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complete response of a primary cutaneous T-cell-rich B cell lymphoma treated with interferon alpha2a.
    Wollina U
    J Cancer Res Clin Oncol; 1998; 124(2):127-9. PubMed ID: 9654196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indolent primary cutaneous B-cell lymphoma: experience using systemic rituximab.
    Morales AV; Advani R; Horwitz SM; Riaz N; Reddy S; Hoppe RT; Kim YH
    J Am Acad Dermatol; 2008 Dec; 59(6):953-7. PubMed ID: 18817999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Anti-CD20 antibodies in primary cutaneous B-cell lymphoma. Initial results in dermatologic patients].
    Gellrich S; Muche JM; Pelzer K; Audring H; Sterry W
    Hautarzt; 2001 Mar; 52(3):205-10. PubMed ID: 11284065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.